Mode
Text Size
Log in / Sign up
Phase 4 N=102 Randomized Double-blind Treatment

Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures

Pain, Postoperative · Femur Fracture

Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Apr 2018
Primary outcome: Primary: Visual Analog Scale Pain Assessment — 5.0; 5.0; 1.6; 3.2 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ropivacaine (Drug); Epinephrine (Drug); Morphine (Drug); 0.9% sodium chloride solution (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Iowa
Primary completion
Aug 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analog Scale Pain Assessment
5.0; 5.0; 1.6; 3.2; 1.0; 5.0
SECONDARY
Total Narcotic Consumption
5.0; 9.7

Summary

The purpose of this study is to determine the efficacy and safety of a peri-incisional multimodal injection for post-operative pain control following operative management of femur fractures. Enrolled subjects will be prospectively randomized into either the peri-incisional injection or control cohorts. Patients will be treated with standard of care surgical techniques by the treating orthopaedic surgeon for the patient's specific fracture pattern. The patients randomized into the injection cohort will receive an intra-operative injection with 400 mg ropivacaine, 0.6 mg epinephrine, 5 mg and morphine into the local superficial and deep peri-incisional tissues while under general anesthesia. Visual analog pain scores will be collected every 4 hours after surgery for the first two post-operative days. Total narcotic consumption will also be recorded over eight hour intervals for the first two post-operative days. Medication related side effects will be monitored. The investigators hypothesize that the peri-incisional injection cohort will demonstrate an improved pain profile and utilize less parenteral narcotic analgesia in the early post-operative period.

Eligibility Criteria

Inclusion Criteria

  • Patients who sustained an acute femur fracture in any anatomic region (subcapital, basicervical, intertrochanteric, subtrochanteric, diaphyseal, distal metaphyseal, or distal articular)
  • Age ≥18 years
  • Indicated for definitive operative management at a single Level 1 trauma center

Exclusion Criteria

  • Revision procedures
  • Temporizing procedures (irrigation and debridement, external fixation)
  • Regular narcotic use
  • Psychiatric illness
  • Dementia
  • Neuromuscular deficit
  • Allergy/intolerance to cocktail ingredients
  • Clinical status that precludes verbal pain assessment (e.g. major intracranial trauma)
  • Refusal to participate
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02793947). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search